All the Drug Class Drugs
α1 Blocker. Alfuzosin (HCl) 10 mg. TABS: 30. 1 tab aft. even. meal. Funct.
sympt. BPH when surg. delayed,
during severe sympt. adenoma espec.
in elderly.
TABS: 30. 1 tab dly aft. meal for 3-4
days, incl. 1 day aft. cath. removed.
Adjuv. tmt. catheter in acute urin. retent.
in BPH. Tmt. certain funct. sympts.
benign prost. hypertrophy.
C/I: Hypersens; orthostat. hypertens,
impair. liver funct.
α1 Blocker. Alfuzosin HCl 10 mg. E.R. TABS: 30. 10 mg dly, immed. aft.
even. meal. Swallow whole with fluid.
Not to be crushed, chew. or divid.
Start ther. on day of insert. of urethral
cath. Tmt. 3-4 days, i.e. 2-3 days
during catheterizat. and 1 day follow.
removal.
Tmt. funct. sympts. BPH, espec. if surg.
delayed. Adjuv. tmt. to cathet. in acute
urinary retent. rel. to BPH.
C/I: Known hypersens., postural
hypotens., liver fail., severe kidney fail.,
combinat. with other alpha 1 blockers,
child.
5-α Reductase Inhibitor, α1 Blocker. Dutasteride 0.5 mg, Tamsulosin HCl 0.4 mg. 5-a Reductase Inhibitor/Alpha 1 Blocker. Dutasteride 0.5 mg, tamsulosin 0.4 mg.
CAPS: 30. 1 cap. dly. See lit.
Tmt. mod. to severe symp. BPH. Reduc. risk of acute urin. reten. (AUR) and surgery in pts. with mod. to severe sympt. of BPH.
C/I: Hyperses., women, child., adolesn., pts. with a hist. of orthost. hypotension, pts. with severe hepat. impair.
α1 Blocker. Phenoxybenzamine HCl 10 mg. CAPS: 30. Pheochrom: 20-60 mg dly.,
Urin. retent: 10 mg 3 x dly. See lit.
Pheochromocytoma, urin. retent, BPH
and neurogen. bladder.
5-α Reductase Inhibitor, α1 Blocker. Dutasteride 0.5 mg, Tamsulosin HCl 0.4 mg. CAPS: 30. 1 cap orally 30 mins. aft. same
meal each day.
Tmt. mod.-severe sympts. BPH. Reduct.
risk acute urin. retent. (AUR), surg. in pts.
with mod.-severe sympts. BPH.
5-α Reductase Inhibitor, α1 Blocker. Dutasteride 0.5 mg, Tamsulosin HCl 0.4 mg. Hard caps.0.5mg + 0.4 mg
1 cap/day
Treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH). Reduction in the risk of acute urinary retention (AUR) and surgery in patients with moderate to severe symptoms of BPH.
C/I: women, child. and adolesc. – hypersens. incl. to other 5-alpha reductase inhib., pts with sev. hepatic impairm.
